Table 3.

Summary of time‐to‐event analysis for the primary endpoint

Group	Benazepril (n = 24)		Placebo (n = 25)		P Value
	Number Reaching Endpoint/Censored	Renal Survival Time (days)	Number Reaching Endpoint/Censored	Renal Survival Time (days)
		Median (95% CI)		Median (95% CI)
All dogs	14/10	305 (53–575)	12/13	287 (152–NA)	.53
UPC >0.5	13/7	196 (53–420)	11/4	158 (15–287)	.12
UPC ≤0.5	1/3	NA (18–NA)	0/8	NA	.16
Plasma creatinine >440 μmol/L	5/0	90 (7–305)	3/0	21 (9–291)	.83
Plasma creatinine ≤440 μmol/L	9/10	420 (53–NA)	9/13	287 (152–NA)	.71
180< plasma creatinine ≤440 μmol/L	8/5	346 (22–575)	7/9	216 (92–NA)	.51
Plasma creatinine ≤180 μmol/L	0/2	NA	1/3	NA (84–NA)	.48
UPC >0.5 & plasma creatinine ≤440 μmol/L	8/7	346 (53–575)	8/4	158 (15–216)	.080

P values were calculated with the log‐rank test.

The primary endpoint was “treatment failure” defined as “the occurrence of death or euthanasia or the need for administration of parenteral fluids related to renal failure”. The primary endpoint variable (renal survival time) was the time from inclusion to the occurrence of the primary endpoint.

Censored cases became no longer available for analysis before or without reaching the defined endpoint.